Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

NCT02296918 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Prolymphocytic Leukemia

Interventions

DRUG: acalabrutinib
DRUG: Obinutuzumab
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Acerta Pharma BV